Results 41 to 50 of about 22,968 (195)

Clinicopathological and targeted exome gene features of a patient with metastatic acinic cell carcinoma of the parotid gland harboring an ARID2 nonsense mutation and CDKN2A/B deletion [PDF]

, 2015
We describe the presentation, treatment, clinical outcome, and targeted genome analysis of a metastatic salivary acinic cell carcinoma (AciCC). A 71-year-old male presented with a 3 cm right tail of a parotid lesion, first detected as a nodule by the ...
Momand, Jamil, Palma-Diaz, Fernando, Shibuya, Terry Y, Warner, Wayne A, Wong, Deborah J   +4 more
core   +4 more sources

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

Targeting CDK6 and BCL2 Exploits the MYB Addiction of Ph+ Acute Lymphoblastic Leukemia [PDF]

, 2018
Philadelphia chromosome–positive acute lymphoblastic leukemia (Phþ ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1–dependent and –
Addya, Sankar, Calabretta, Bruno, De Dominici, Marco, Ferrari, Anna, Fortina, Paolo, Iacobucci, Ilaria, Mariani, Samanta A., Martinelli, Giovanni, Peterson, Luke F., Porazzi, Patrizia, Rambaldi, Alessandro, Soliera, Angela Rachele, Spinelli, Orietta   +12 more
core   +1 more source

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. [PDF]

, 2018
We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets
Aronow, Bruce J., Doench, John G., Grimes, H. Leighton, Lal, Ashish, Lieberman, Judy, McGlinn, Edwina, Meyer, Sara E., Morris, Patrick J., Muench, David E., Newkold, Tess J., O\u27Brien, Eric, Orr, Emily, Perentesis, John P., Rogers, Andrew M., Salomonis, Nathan, Thomas, Craig J.   +15 more
core   +2 more sources

TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression

Cell Death Discovery
Palbociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer by suppressing cell proliferation. However, monotherapy with palbociclib was discouraging in prostate cancer, calling for a mechanism-based effective therapy. In this study, we
Yangyi Zhang, Chenyu Liu, Yalan Yang, He Ren, Tianyi Ren, Yinuo Huang, Shinan Zhang, Qiang Sun, Hongyan Huang   +8 more
doaj   +1 more source

Updates on managing advanced breast cancer with palbociclib combination therapy

Therapeutic Advances in Medical Oncology, 2018
Background: The objective of this study was to review the pharmacology, efficacy, and safety of palbociclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of advanced breast cancer (ABC).
Teresa M. McShane, Thomas A. Wolfe, Joanne C. Ryan   +2 more
doaj   +1 more source

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval

Breast Cancer Research, 2018
Background Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy.
J. K. Kish, M. A. Ward, D. Garofalo, H. V. Ahmed, L. McRoy, J. Laney, G. Zanotti, J. Braverman, H. Yu, B. A. Feinberg   +9 more
doaj   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth [PDF]

, 2017
Adipose tissue secretes a plethora of adipokines as evidenced by characterization of subcutaneous and visceral adipose tissue secretomes. However, adipose tissue composition and secretion pattern is depot and disease dependent, influencing the adipose ...
Bracke, Marc, Braems, Geert, Cocquyt, Veronique, De Wever, Olivier, Denys, Hannelore, Hendrix, An, Lapeire, Lore, Lecoutere, Evelyne, Maynard, Dawn, Müller, Cathérine, Van Bockstal, Mieke, Van den Broecke, Rudy, Vandesompele, Jo   +12 more
core   +2 more sources

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Molecular Therapy: Nucleic Acids, 2022
Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT ...
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini   +9 more
doaj   +1 more source